Publication of the 2018 Registration Document
Paris (France), April 8, 2019 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the publication of the Company’s 2018 Registration Document.
The 2018 Registration Document, filed with the French Market Authorities (Autorité des Marchés Financiers) on April 5, 2019, is available to the public free of charge upon request, as per current legal regulations, at on the Company’s website under section : Investors/Regulated information/Registration documents.
Copies of the Registration Document are also available at the head offices of Onxeo – 49 Boulevard du Général Martial Valin, 75015 Paris.
The annual financial report, the report on corporate governance, as well as the auditors’ reports and information on the fees paid to the statutory auditors in 2018 are included in this Registration Document.